NF2 gene expression in sporadic meningiomas: Relation to grades or histotypes real time-PCR study

Neuropathology

Volumn 27, Issue 1, 2007, Pages 36-42

  Buccoliero, Anna M ^a   Castiglione, Francesca ^a   Degl'Innocenti, Duccio R ^a   Gheri, Chiara F ^a   Garbini, Francesca ^a   Taddei, Antonio ^a   Ammannati, Franco ^b   Mennonna, Pasquale ^b   Taddei, Gian L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Meningioma; Meningothelial; Merlin; NF2; RT PCR

Indexed keywords

NEUROFIBROMATOSIS TYPE 2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, NEUROFIBROMATOSIS 2; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33846449907     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2006.00737.x     Document Type: Article

References (39)

1. De Vitis LR, Tedde A, Vitelli F et al. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum Genet 1996; 97: 632-637.
2. Perry A, Gutmann DH, Reinfenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004; 70: 183-202.
3. Perry A, Cai DX, Sheithauer B et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropath Exp Neur 2000; 10: 872-879.
4. Luis E, Gutman DH. Meningioma: an update. Curr Opin Neurol 2004; 17: 687-692.
5. Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 2003; 13: 191-202.
6. Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 1999; 59: 5995-5998.
7. Gutmann DH, Donahoe J, Perry A et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000; 10: 1495-1500.
8. Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997; 49: 267-270.
9. Gutmann DH. The neurofibromatosis: when less is more. Hum Mol Genet 2001; 10: 747-755.
10. Rangwala R, Banine F, Borg JP, Sherman LS. Erbin regulates mitogen activated protein (MAP) kinase activation and MAP kinase-dependent interactions between merlin and adherens junction protein complexes in schwann cells. J Biol Chem 2005; 280: 11790-11797.
11. Xu HM, Gutmann DH. Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res 1998; 51: 403-415.
12. Brault E, Gautreau A, Lamarine M, Callebaut I, Thomas G, Goutebroze L. Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain. J Cell Sci 2001; 114: 1901-1912.
13. Grönholm M, Teesalu T, Tyynelä J et al. Characterization of the NF2 protein merlin and the ERM protein ezrin in human, rat, and mouse central nervous system. Mol Cell Neurosci 2005; 28: 683-693.
14. James MF, Manchanda N, Gonzalez-Agosti C, Hartwig JH, Ramesh V. The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J 2001; 356: 377-386.
15. Ramesh V. Merlin and the ERM proteins in Schwann cells, neurons and growth cones. Nat Rev Neurosci 2004; 5: 462-470.
16. Kim H, Kwak NJ, Lee JY et al. Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 2004; 279: 7812-7818.
17. Denisenko-Nehrbass N, Goutebroze L, Galvez T et al. Association of Caspr/paranodin with tumour suppressor schwannomin/merlin and beta1 integrin in the central nervous system. J Neurochem 2003; 84: 209-221.
18. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 2003; 17: 1090-1100.
19. Chen Y, Gutman DH, Haipek CA, Martinsen BJ, Bronner-Fraser M, Krull CE. Characterization of chicken NF2/merlin indicates regulatory roles in cell proliferation and migration. Dev Dynam 2004; 229: 541-554.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001; 25: 402-408.
21. Louis DN, Scheithauer BW, Budka H et al. Meningiomas. In: Kleihues P, Cavenee K (eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000; 176-189.
22. Caldarella A, Buccoliero AM, Marini M, Taddei A, Mennonna P, Taddei GL. Oncocytic meningioma: a case report. Pathol Res Pract 2002; 198: 109-113.
23. Ironside JW, Moss TH, Louis DN et al. Diagnostic Pathology of Nervous System Tumours. London: Churchill Livingstone, 2002.
24. Ruttledge MH, Sarrazin J, Rangaratnam S et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994; 6: 180-184.
25. Lekanne Deprez RH, Bianchi AB, Groen NA et al. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 1994; 54: 1022-1029.
26. McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 1997; 11: 1253-1265.
27. Kalamarides M, Niwa-kawakita M, Leblois H et al. NF2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in mouse. Gene Dev 2002; 16: 1060-1065.
28. Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C et al. Universal absence of merlin, but not other ERM family members in schwannomas. Am J Pathol 1997; 151: 1649-1654.
29. Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubic M. Reduced expression of schwannomin/merlin in human sporadic meningiomas. Neurosurgery 1997; 40: 578-587.
30. Gutmann DH, Geist RT, Xu HM, Kim JS, Saporito-Irwin S. Defect in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 1998; 7: 335-345.
31. Den Bakker MA, van Tilborg AAG, Kros Jm Zwarthoff EC. Truncated NF2 proteins are not detected in meningiomas and schwannomas. Neuropathology 2001; 21: 168-173.
32. Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 1994; 269: 23387-23390.
33. Sherman L, Xu HM, Geist RT et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997; 15: 2505-2509.
34. Kimura Y, Koga H, Araki N et al. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat Med 1998; 4: 915-922.
35. Kaneko T, Yamashima T, Tohma Y et al. Calpa-independent proteolysis of merlin occurs by oxidative stress in meningiomas: a novel hypothesis of tumorigenesis. Cancer 2001; 92: 2662-2672.
36. Wellenreuther R, Kraus JA, Lenartz D et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningiomas. Am J Pathol 1995; 146: 827-832.
37. Perry A, Giannini C, Raghavan R et al. Aggressive phenotypic and genotypic features in pediatric and NF-2.associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001; 10: 994-1003.
38. Wellenreuther R, Waha A, Vogel Y et al. Quantitative analysis of neurofibromatosis type 2 gene transcript in meningiomas supports the concept of distinct molecular variants. Lab Invest 1997; 6: 601-606.
39. Evans JJ, Jeun SS, Lee JH et al. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg 2001; 94: 111-117.